Coherus Will Prioritize Oncology As Inflammation Takes A Back Seat

Sandoz Enbrel Ruling Leads Company To Chop Asset

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.

Invest
Coherus will invest R&D dollars into oncology and immuno-oncology • Source: Shutterstock

Fresh from a more than $220m round of financing and with operations churning out cash, Coherus BioSciences says it will “continue to focus in oncology with respect to our new product efforts and that capital deployment,” as the US-based player appeared to rule out any further investment in autoimmune disorders beyond its biosimilar Humira (adalimumab) candidate.

On the back of Coherus debuting its sole product, the chemotherapy drug Udenyca (pegfilgrastim-cbqv) in January 2019, management described oncology...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.